DexCom, Inc. (NASDAQ:DXCM) Stake Raised by Zevenbergen Capital Investments LLC

Zevenbergen Capital Investments LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 9.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 387,168 shares of the medical device company’s stock after purchasing an additional 34,020 shares during the quarter. Zevenbergen Capital Investments LLC’s holdings in DexCom were worth $30,110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Versant Capital Management Inc acquired a new stake in shares of DexCom in the fourth quarter valued at $25,000. Private Trust Co. NA grew its stake in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC grew its position in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom during the 4th quarter valued at about $38,000. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of research analyst reports. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Price Performance

Shares of DXCM stock opened at $73.80 on Monday. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $28.84 billion, a price-to-earnings ratio of 51.61, a PEG ratio of 2.30 and a beta of 1.28. The firm’s 50 day moving average is $83.33 and its 200-day moving average is $77.03. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.